Liproxstatin-1_950455-15-9_DataSheet_MedChemExpress

合集下载

liproxstatin-1结构

liproxstatin-1结构Liproxstatin-1是一种小分子抑制剂，它的结构如下：Liproxstatin-1的分子式为C30H24N2O10S，分子量为608.6克/摩尔。

它是一种灰黄色的固体，其溶解度较低，但可以在有机溶剂中稳定溶解。

Liproxstatin-1的结构中包含了一个核苷酸，一个酮醛，和一个酰胺。

它的核苷酸部分包括一个含有一条碳链的六元环，以及一个含有一个氧原子的五元环。

在这两个环之间，有一个含有一对氮原子和一个含有硫原子的五元环。

这个核苷酸环上还连接着一个酮醛基团和一个酰胺基团。

酮醛基团与核苷酸环的一个碳原子相连，并包括一个含有两个氢原子的三元环。

而酰胺基团与酮醛基团相连，并包括一个含有一个氧原子的四元环。

Liproxstatin-1的分子结构使其具有抗氧化和抗炎症的作用。

它可以通过抑制一氧化氮合酶和过氧化氢酶的活性，减少活性氧的产生，从而防止氧化应激的发生。

此外，Liproxstatin-1还可以减少炎症反应中介物的产生，抑制炎症细胞的活化，从而降低炎症反应的强度和持续时间。

Liproxstatin-1的抗氧化和抗炎症作用使其在多种疾病的治疗中具有潜力。

研究已经表明，Liproxstatin-1可以通过减少氧化应激和炎症反应来抑制肿瘤的生长和转移。

此外，Liproxstatin-1还可以保护心脏、肝脏和肾脏等器官免受氧化应激和炎症的损伤。

值得注意的是，Liproxstatin-1具有一定的毒性。

一些研究结果显示，Liproxstatin-1可以对正常细胞产生负面影响。

因此，在使用Liproxstatin-1作为药物时，需要仔细评估其安全性和有效性，并在合适的剂量和适当的治疗期限内使用。

总之，Liproxstatin-1是一种具有抗氧化和抗炎症作用的小分子抑制剂。

它的分子结构使其具有广泛的应用潜力，但同时也要注意其毒性和安全性的问题。

随着对Liproxstatin-1机制和作用的深入研究，相信它将在多种疾病的治疗中发挥重要的作用。

CelLyticTM系列蛋白裂解液

CelLyticTM系列蛋白裂解液
高效率操作步骤简单,省时高得率得率远优于传统冻融或超声法高活性温和非变性条件下抽提活性蛋白高兼容与蛋白酶抑制剂、鳌合剂、离液剂等很好兼容抽提的蛋白无需去除CelLyticTM 试剂即可进行下游实验：亲和纯化 Western blot 凝胶迁移检测报告基因检测……
566.28 2136.42 566.28 3758.04 2535.39 3938.22
501.93 3320.46
566.28 2084.94 3989.7
527.67 3629.34 5302.44
促销价¥
384.81 2375.80 685.97 2375.80 409.91 1505.79 2651.86 1054.05 1648.00 393.18 1187.90 217.50 711.07 4341.69 368.08 1271.56
哺乳动物细胞和组织裂解
C2978
CelLytic™ M Cell Lysis Reagent
C3228
CelLytic™ MT Cell Lysis Reagent
CE0500 NXTRACT
R0278
CelLytic™ MEM Protein Extraction Kit CelLytic™ NuCLEAR™ Extraction Kit For mammalian tissue or cultured cells RIPA Buffer
P8215
Protease Inhibitor Cocktail for use with fungal and yeast extracts
P8465
Protease Inhibitor Cocktail for use with bacterial cell extracts

hss-p-5.75.09 - hyaluronic acid derivatives说明书

5.75.09Section:Prescription DrugsEffective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject:Hyaluronic Acid DerivativesPage:1 of 7Last Review Date:March 13, 2020Hyaluronic Acid DerivativesDescriptionDurolane, Euflexxa, GelSyn-3, GenVisc 850, Hyalgan , SodiumHyaluronate, Supartz , Synojoynt*, Triluron, TriVisc, Visco-3 (sodium hyaluronate)Gel-ONE , Hymovis, Monovisc, Orthovisc (hyaluronan)Synvisc, Synvisc-One (hylan G-F 20)Bolded medications are the preferred products*These medications are included in this policy but are not available in the market as of yetBackgroundOsteoarthritis of the knee is a disease in which the elastoviscous property of the synovial fluid in the knee joint becomes diminished, resulting in less protection and shock absorption. Durolane, Euflexxa, Gel-One, GelSyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Sodium Hyaluronate, Synvisc, Synvisc-One, Supartz, Synojoynt, Triluron, TriVisc, Visco-3 are hyaluronan derivatives that are injected into the knee joints to increase the elastoviscous properties of arthritic joint fluid and slow its outflow from the joint . The goal of therapy is torestore the viscoelasticity in the affected joints, thereby decreasing pain, improving mobility, and restoring the natural protective functions (1).The American College of Rheumatology (ACR) updated its guidelines for the treatment of osteoarthritis (OA) of the knee in 2012. In mild symptomatic OA, treatment may be limited toFederal Employee Program® 1310 G Street, N.W.Washington, D.C. 20005 202.942.1000Fax 202.942.1125Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 2 of 7patient education, physical and occupational therapy and other non-pharmacologic modalities. Nonpharmacologic modalities strongly recommended for the management of knee OA were aerobic, aquatic, and/or resistance exercises as well as weight loss for overweight patients. Nonpharmacologic modalities conditionally recommended for knee OA included medial wedge insoles for valgus knee OA, subtalar strapped lateral insoles for varus knee OA, medially directed patellar taping, manual therapy, walking aids, thermal agents, tai chi, self-management programs, and psychosocial interventions. Pharmacologic modalities conditionally recommended for the initial management of patients with knee OA included acetaminophen, oral and topical NSAIDs, tramadol, and intraarticular corticosteroid injections (1).Regulatory StatusFDA-approved indication: Hyaluronic acid derivatives are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy, simple analgesics (e.g., acetaminophen), NSAIDs, tramadol, or intra-articular steroid injections (2-18).The hyaluronic acid derivatives are contraindicated for use in patients with known hypersensitivity to hyaluronan (sodium hyaluronate) preparations. Orthovisc lists hypersensitivity to gram positive bacterial proteins as an additional contraindication (4). Caution should be exercised when Gel-One, Hyalgan, Visco-3, Synvisc, Synvisc-One, Supartz, and Triluron are administered to patients with allergies to avian proteins, feathers, and egg products (3-8, 18).Hyaluronic acid derivatives are contraindicated to treat patients with knee joint infections, infections or skin diseases in the area of the injection site (2-17).A treatment cycle for most of the hyaluronan derivatives typically involves multiple weekly injections. Euflexxa, GelSyn-3, Sodium Hyaluronate, Synvisc, Triluron, TriVisc, and Visco-3 are given for a total of three injections. Orthovisc is given for three or four injections. GenVisc 850, Supartz and Hyalgan are given for a total of three or five injections. Durolane, Gel-One, Synojoynt, and Synvisc-One differ from the other hyaluronan derivatives in that it only requires one injection. Repeat courses of hyaluronan derivatives may be administered if symptoms return (2-18).Upon the basis of high quality supporting evidence, the American Academy of Orthopedic Surgeons cannot recommend using hyaluronic acid for patients with symptomatic osteoarthritis of the knee (19).Related policiesSection: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 3 of 7Hyaluronate PowderPolicyThis policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.Hyaluronic acid derivatives may be considered medically necessary for the treatment of osteoarthritis of the knee and if the conditions indicated below are met.Hyaluronic acid derivatives may be considered investigational for all other indications.Prior-Approval RequirementsAge18 years or older (22 or older for Synvisc, Synvisc-One, and TriVisc)DiagnosisPatient must have the following:Osteoarthritis of the kneeAND ALL of the following:1. Inadequate response to TWO or more of the following conservative non-pharmacologic therapy:a. Cardiovascular (aerobic) activity, such as: walking, biking, stationarybike, aquatic exerciseb. Resistance exercisec. Weight reduction (for persons who are overweight)d. Participation in self-management programse. Wear of medially directed patellar tapingf. Wear of wedged insolesg. Thermal agentsh. Walking aidsi. Physical therapyj. Occupational therapy2. Inadequate response, intolerance, or contraindication to TWO or more of thefollowing:Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 4 of 7a. Acetaminophenb. Oral NSAIDsc. Topical NSAIDs3. Inadequate response, intolerance, or contraindication to intra-articularsteroid injections in which efficacy lasted less than 8 weeks4. Radiologic confirmation of Kellgren-Lawrence Scale score of grade 2 orgreater5. NO dual therapy with another hyaluronic acid injectable6. Non-preferred medications only: Patient MUST have tried at least TWO ofthe preferred products unless the patient has a valid medical exception (e.g.inadequate treatment response, intolerance, contraindication)Prior – Approval Renewal RequirementsAge18 years or older (22 or older for Synvisc, Synvisc-One, and TriVisc)DiagnosisPatient must have the following:Osteoarthritis of the kneeAND ALL of the following:1. Documentation of improvement in pain with previous course of treatment2. At least 12 months has elapsed since last injection of the prior treatmentcycle3. Documentation of reduction of dosing of NSAIDs or other analgesicsduring the 12 month period following the last injection of the prior treatmentcycle4. NO dual therapy with another hyaluronic acid injectable5. Non-preferred medications only: Patient MUST have tried at least TWOof the preferred products unless the patient has a valid medical exception(e.g. inadequate treatment response, intolerance, contraindication) Policy GuidelinesPre - PA AllowanceNoneSection: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 5 of 7Prior - Approval LimitsDuration12 monthsQuantity One course of therapy for each kneePrior – Approval Renewal LimitsSame as aboveRationaleSummaryOsteoarthritis of the knee is a disease in which the elastoviscous property of the synovial fluid in the knee joint becomes diminished, resulting in less protection and shock absorption. Durolane, Euflexxa, Gel-One, GelSyn-3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Sodium Hyaluronate, Synvisc, Synvisc-One, Supartz, Synojoynt, Triluron, TriVisc, Visco-3 are hyaluronan derivatives that are injected into the knee joints to increase the elastoviscous properties of arthritic joint fluid and slow its outflow from the joint. The goal of therapy is to restore the viscoelasticity in the affected joints, thereby decreasing pain, improving mobility, and restoring the natural protective functions (1-18).Prior approval is required to ensure the safe, clinically appropriate and cost effective use of the hyaluronic acid derivatives while maintaining optimal therapeutic outcomes.References1. American College of Rheumatology, Subcommittee on Osteoarthritis Guidelines.Recommendations for the medical management of osteoarthritis of the hip and knee:2012 update. Arthritis Care & Research 2012; 64(4):465-474.2. Euflexxa [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; July 2016.3. Hyalgan [package insert]. Parsippany, NJ: Fidia Pharma USA Inc.; May 2014.4. Orthovisc [package insert]. Woburn, MA: Anika Therapeutics; June 2005.5. Supartz [package insert]. Durham, NC: Bioventus LLC; April 2015.6. Synvisc [package insert]. Ridgefield, NJ: Genzyme Corp.; December 2014.7. Synvisc-One [package insert]. Ridgefield, NJ: Genzyme Corp.; September 2014;8. Gel-One [package insert]. Warsaw, IN: Zimmer Inc.; May 2011.9. Monovisc [package insert]. Bedford, MA: Anika Therapeutics; December 2013.10. Hymovis [package insert]. Parsippany, NJ: O Fidia Pharma USA Inc.; October 2015.Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 6 of 711. GenVisc 850 [package insert]. Doylestown, PA: OrthogenRx Inc.; January 2015.12. GelSyn-3 [package insert]. Durham, NC: Bioventus LLC; January 2016.13. Durolane [package insert]. Durham, NC: Bioventus LLC; November 2017.14. Visco-3 [package insert]. Warsaw, IN: Zimmer, Inc.; May 2017.15. Sodium Hyaluronate [package insert]. North Wales, PA: Teva Pharmaceuticals USA,Inc.; March 2019.16. Synojoynt [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.;September 2019.17. TriVisc [package insert]. Doylestown, PA: OrthogenRx, Inc.; September 2018.18. Triluron [package insert]. Florham Park, NJ: Fidia Pharma USA Inc.; March 2019.19. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee.Evidence-based guideline 2nd edition. May 2013.Policy HistoryDate Action ReasonJanuary 2012 Added minimum age - only approved for adultsDecember 2012 Annual editorial review and reference updateDecember 2013 Annual editorial review and reference updateMarch 2014 Annual editorial reviewAddition of examples of non-pharmacological agents and agents of priorfailure medications.April 2014 Line-Addition of Monovisc to PAMarch 2015 Annual criteria review and reference updateMarch 2016 Change from one tried and failed to two tried and failed non-pharmacologic and pharmacologic therapies and addition of the tried and failed of intra-articular steroid and radiologic confirmation of Kellgren-Lawrence Scalescore of grade 2 or greaterAddition of HymovisPolicy # change from 5.11.04 to 5.75.09May 2016 Addition of GelSyn-3 and GenVisc 850December 2016 Annual editorial review and reference updateAdded: no dual therapy with another hyaluronic acid injectableMarch 2017 Bolded preferred products in the title pageJuly 2017 GelSyn-3 has been changed to preferredSeptember 2017 Annual reviewDecember 2017 Addition of Durolane and Visco-3March 2018 Annual editorial reviewRemoval of Tramadol from the T/F listSeptember 2019 Annual review and reference update. Addition of Sodium Hyaluronate,Synojoynt, and TriViscSection: Prescription Drugs Effective Date: April 1, 2020 Subsection: Neuromuscular Drugs Original Policy Date: June 9, 2011 Subject: Hyaluronic Acid Derivatives Page: 7 of 7December 2019 Annual review. Addition of requirement to trial preferred products January 2020 Addition of TriluronMarch 2020 Annual reviewKeywordsThis policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 13, 2020 and is effective on April 1, 2020.。

Roche_Xtreme GeneHP_protocal

0910.06479774001ቢ

The recommended starting concentration is a 3:1. For most cell types, these X-tremeGENE HP DNA Transfection Reagent to DNA ratios provide excellent transfection efficiency. Further optimization may increase transfection efficiency in your particular application. In addition to varying the ratio, other parameters may also be evaluated, such as the amount of transfection complex added. For additional optimization guidelines, see Section 3, Troubleshooting and visit . Plasmid DNA • For best results, accurately determine the plasmid DNA concentration using 260-nm absorption; estimates of DNA by measuring gel band density are not recommended. Determine DNA purity using a 260 nm/280 nm ratio (the optimal ratio is 1.8). • Prepare the plasmid DNA solution using sterile TE (Tris/EDTA) buffer or sterile water at a concentration of 0.1 to 2.0 µg/µl. • Use high quality DNA preparation kits to obtain endotoxin-free DNA. Cell Culture Conditions • Minimize intra- and inter-experimental variance in transfection efficiency using cells that are regularly passaged, proliferating well in a log-growth phase, and plated at a consistent density. • For best results, accurately quantify cell concentration using a hematocytometer or automated system. • Cells must be healthy and free of Mycoplasma. • Cells should have a low passage number to achieve best results. Other Media Additives In some cell types, antimicrobial agents (e.g., antibiotics and fungicides) commonly included in cell-culture media may adversely affect the transfection efficiency of X-tremeGENE HP DNA Transfection Reagent. If possible, exclude additives in initial experiments. Once high-efficiency conditions have been established, these components can be added back while monitoring transfection results. Cell growth and/or transfection efficiency may be affected by variations in serum quality and medium formulations. Verification of Vector Function Optimize transfection conditions using a known positive-control reporter gene construct before transfecting cells with a new vector construct: • Determine transfection efficiency using a reporter gene assay, such as ␤-Gal*, Luciferase*, or SEAP*. • Sequence flanking vector insert regions to verify the integrity of your new construct. 2.2 Transfection Procedure Adherent Cells: Plate cells approximately 24 hours before transfection making sure cells are at the optimal concentration in the appropriate cell culture vessel. Suspension Cells: Plate freshly passaged cells at optimal concentration.

liproxstatin-1结构

liproxstatin-1结构Liproxstatin-1是一种新型的药物，具有潜力治疗多种疾病，包括神经退行性疾病，心血管疾病和肿瘤等。

它是一种蛋白质复合物，其中包括白介素-6诱导亚基共同激活蛋白（STAT3）的抑制剂和蛋白酶体蛋白酶α的抑制剂。

Liproxstatin-1是通过通过选择性抑制STAT3和蛋白体蛋白水平来产生其药效的。

这种化合物主要用于治疗由炎症引起的疾病，特别是自身免疫疾病和癌症等疾病。

其作用机制是通过抑制NF-κB和STAT3信号通路的激活来抑制炎症。

此外，它还可以对多种细胞因子进行抑制，例如IL-6等。

Liproxstatin-1最初是由日本的一家制药公司发现的，目前已经被引起了学术界和产业界的广泛关注。

其分子结构为C20H17NO4，呈深棕色粉末，可溶于DMSO和乙醇中，而在水中的溶解度较低。

从药理学的角度来看，Liproxstatin-1的特殊结构和药效的产生有着密切的关系。

在分子结构中，Liproxstatin-1包含了一个苯环和一个五元杂环，而杂环内部还有一个双键和一个亚胺基团。

在苯环中，有两个取代基，其中一个是碘原子，另一个是甲氧基团。

这种分子结构使其能够与蛋白质和其他生物大分子结合，并对其产生影响。

此外，由于Liproxstatin-1本身具有强抗氧化能力，能够清除自由基，从而减少氧化应激对细胞的影响。

这些特性使其在治疗神经退行性疾病和心血管疾病等方面具有潜在的作用。

总之，Liproxstatin-1作为一种新型的药物，具有潜力治疗多种疾病，其分子结构和药效的产生密切相关。

对于该化合物的进一步研究和开发将有望为人类健康和医疗事业做出重大贡献。

QPCR及QRT-PCR系列产品

Invitrogen的ICFC系列产品促销1．QPCR及QRT-PCR系列产品Invitrogen公司专门为中国客户提供的定量PCR试剂盒，结合了 UDG 防止残余污染技术和SYBR® Green I 荧光染料（存在于SYBR® Green I荧光定量PCR试剂盒中），在美国接受了严格的质量监控，可提供极高灵敏度的目的序列定量检测，线性剂量低，反应浓度范围很大。

qPCR Supermix-- 即用型反应剂，专为高特异性、实时定量DNA扩增设计UDG-- 防止携带污染物，减少克隆片段假阳性结果ROX参考染料-- 适用ABI仪器的校正染料产品信息活动时间：即日起至2009年4月30日2．Gibco南美胎牛血清即日起凡优惠价¥1780购买Gibco胎牛血清500ml（目录号:C2027050）即可获赠送价值¥250现金抵用券。

您可以凭现金抵用券在英韦创津公司购买任何商品，此券有效期至2009年5月31日。

产品信息活动时间：即日起至2009年4月30日独特的采集方式：GIBCO采用无菌心脏穿刺的方式采血原装直送，避免污染：原产地采集、加工、检测、包装。

完善的质控：采集、处理、检测、运输等环节都有文件和证书。

3．Invitrogen TA Cloning克隆产品专门用于克隆Taq聚合酶扩增的PCR产物。

采用pCR载体，能产生80%以上的重组产物，90%以上重组产物都包含插入片段。

产品信息活动时间：即日起至2009年5月31日附：pCR载体优点及图谱：3’-T突出端可直接连接Taq扩增的PCR产物可选择T7或T7和Sp6启动子进行体外RNA转录和测序侧向EcoRⅠ位点的通用多接头位点方便了插入片段的切离可以选择卡那霉素或氨苄青霉素进行筛选非常简便的蓝/白克隆筛选具有M13正向和反向引物位点，方便测序4．GIBCO液体培养基系列产品创立近50年的历史，品质优秀，产品种类丰富；为了中国用户利益，特建立国内生产线；所有产品，从原材料到生产全部按照GIBCO质量标准进行，每批均送抵美国公司总部质检合格后，才在国内销售。

自-罗氏proGRP产品说明书

【产品名称】通用名称:胃泌素释放肽前体检测试剂盒(电化学发光法)英文名称:ProGRＰ【包装规格】100测试/盒【预期用途】主要用途用于体外定量检测人血浆和血清中的胃泌素释放肽前体(ＰｒoGRＰ)。

该分析结合其他临床方法可辅助用于肺癌的鉴别诊断和小细胞肺癌患者的管理。

结果必须根据标准临床诊疗指南结合其他方法进行解释。

Elecsys和cobas e免疫分析仪的工作原理是电化学发光免疫分析“ＥCLIＡ”。

临床应用胃泌素释放肽（GRP）是一种重要的调节分子,和人体许多生理功能、病理状态有关。

它是一种胃肠激素,是哺乳动物同源的两栖动物蛙皮素,最初从猪胃粘膜中分离,广泛分布于哺乳动物的神经系统、胃肠道和呼吸道。

1随着信号肽解离,它的148个氨基酸的前蛋白原进一步分解生成2７个氨基酸的胃泌素释放肽和68个氨基酸的胃泌素释放肽前体(PrｏGRP)。

由于胃泌素释放肽的半衰期很短,只有2分钟，不可能在血中检测到。

因此研发出一种检测胃泌素释放肽前体（３1-98)的测定法，一个羧基端区域,常见于三种类型的人胃泌素释放肽前体剪接变体。

现已证明血清胃泌素释放肽前体(３1-9８)可作为小细胞肺癌(SCLC)病人的可靠标志物。

２,3，４,5Eleｃsys胃泌素释放肽前体检测血浆和血清中的胃泌素释放肽前体（31-98）。

胃泌素释放肽前体和神经特异性烯醇化酶(NＳE）是与神经内分泌源组织和肿瘤有关的两种分子。

胃泌素释放肽前体水平升高见于多种神经内分泌源肿瘤，包括小细胞肺癌、类癌、具有神经内分泌功能的未分化大细胞肺癌、甲状腺髓样癌6、其他神经内分泌恶性肿瘤6以及具有神经内分泌功能的不依赖雄激素的前列腺癌亚组。

7良性疾病中的胃泌素释放肽前体：文献报道胃泌素释放肽前体血清浓度在2-５0pg/mＬ时为正常。

8但是，在一项对包括肝脏疾病在内的良性疾病（肾功能不全除外）病人的研究中，有2.５％的病人胃泌素释放肽前体血清水平＞5０pｇ/mL。

蛋白酶抑制剂混合液(100×PIC)

产品组成：
名称
编号
蛋白酶抑制剂混合液(100×PIC)
使用说明书
PI0015 1ml
PI0015
Storage
5×1mlቤተ መጻሕፍቲ ባይዱ1份
-20℃ 避光
操作步骤（仅供参考）：
1、开盖前，请低速离心一下，以便将黏附于管壁的液体甩至管底。 2、使用时, 根据裂解液的用量加入 1%的蛋白酶抑制剂混合液(100×PIC)，使其终浓度达
北京雷根生物技术有限公司
蛋白酶抑制剂混合液(100×PIC)
产品简介：
蛋白酶抑制剂(Protease Inhibitor)指与蛋白酶分子活性中心上的一些基团结合，使蛋白酶活力下降，甚至消失，但不使酶蛋白变性的物质。蛋白酶抑制剂有很多种，包括 EDTA、 E-64、NaVO3、Bestatin、Leupetin、Pepstatin A、Aprotinin 等，可以有效抑制蛋白的降解，并维持原有的蛋白间相互作用。
到 1×。
注意事项：
1、蛋白酶抑制剂混合液有轻微刺激性，小心操作，同时应避免反复冻融。 2、为了您的安全和健康，请穿实验服并戴一次性手套操作。
有效期：12 个月有效。
相关产品：
产品编号 PI0011 PS0013 PT0001
产品名称苯甲基磺酰氟溶液(PMSF,100mmol/L) RIPA 裂解液(强) BCA 法蛋白定量试剂盒
Leagene 蛋白酶抑制剂混合液 (100 × PIC) 主要由 Leupetin 、 Pepstatin A 、 Aprotinin、E-64 等组成，不含 EDTA。该混合物可以抑制绝大多数蛋白酶活性，包括丝氨酸蛋白酶、半胱胺酸蛋白酶、胃蛋白酶、胰蛋白酶、木瓜蛋白酶等。该蛋白酶抑制剂混合液是 100×的浓缩的 DMSO 溶液，适用于从哺乳动物组织、细胞中提取蛋白质，能够更有效的获得目的蛋白质。提取出来的蛋白可以用于 Western Blot、免疫共沉淀等试验。

安捷伦产品目录

15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ～ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤優秀的溫控設備讓各個 well 都能保持溫度的穩定七吋的高解析度觸控螢幕讓操作上更為簡便可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題

lipofectamineRNAiMAX英文说明书

Lipofectamine™ RNAiMAXCat. No. 13778-075 Size: 0.75 mlCat. No. 13778-150 Size: 1.5 mlStore at +4°C (do not freeze) DescriptionLipofectamine™ RNAiMAX is a proprietary formulation specifically developed for the transfection of siRNA and Stealth™ RNAi duplexes into eukaryotic cells. Lipofectamine™ RNAiMAX provides the following advantages:• High transfection efficiencies in many cell types to minimize background expression from untransfected cells and maximize knockdown.• Minimal cytotoxicity to reduce non-specific effects and cellular stress.• Generally requires low concentrations of RNAi duplexes to obtain high knockdown levels, further minimizing non-specific effects.• A broad peak of optimal transfection activity with minimal cytotoxicity, allowing achievement of high knockdown levels despite differences in cell density, minor pipetting inaccuracies, and other variations.Important Guidelines for Transfection• Reverse transfection (page 2) and forward transfection (page 3) protocols can be used for most cell lines tested. Cell-type specific transfection protocols are available at /RNAi or through Technical Service.• We recommend Opti-MEM® I Reduced Serum Medium (Cat. No. 31985-062) to dilute RNAi duplexes and Lipofectamine™ RNAiMAX before complexing.• Do not add antibiotics to media during transfection as this causes cell death.• Test serum-free media for compatibility with Lipofectamine™ RNAiMAX. • To assess transfection efficiency, we recommend using a KIF11 Stealth™Select RNAi, as described in Assessing Transfection Efficiency (page 2). • Use 10 nM RNAi duplex and indicated procedure as a starting point;optimize transfections as described in Optimizing Transfections (page 3). Quality ControlLipofectamine™ RNAiMAX is tested for absence of microbial contamination with blood agar plates, Sabaraud dextrose agar plates, and fluid thioglycolate medium, for absence of RNAse activity, and functionally by transfection of Stealth™ RNAi and appropriate controls into a reporter cell line.Part No.: 13778.PPS Rev. Date: 11 Jan 2006For research use only. Not intended for any animal or human therapeutic or diagnostic use.For technical support, contact tech_service@.Page 2 Reverse TransfectionUse this procedure to reverse transfect Stealth™ RNAi or siRNA into mammalian cells in a 24-well format (for other formats, see Scaling Up or Down Transfections, page 4). In reverse transfections, the complexes are prepared inside the wells, after which cells and medium are added. Reverse transfections are faster to perform than forward transfections, and are the method of choice for high-throughput transfection. Optimize transfections as described in Optimizing Transfections (page 3), especially if transfecting a mammalian cell line for the first time. All amounts and volumes are given on a per well basis.1. For each well to be transfected, prepare RNAi duplex-Lipofectamine™RNAiMAX complexes as follows.a. Dilute 6 pmol RNAi duplex in 100 µl Opti-MEM® I Medium without serumin the well of the tissue culture plate. Mix gently.b. Mix Lipofectamine™ RNAiMAX gently before use, then add 1 µlLipofectamine™ RNAiMAX to each well containing the diluted RNAimolecules. Mix gently and incubate for 10-20 minutes at roomtemperature.2. Dilute cells in complete growth medium without antibiotics so that 500 µlcontains the appropriate number of cells to give 30-50% confluence 24 hours after plating. Use 20,000-50,000 cells/well for suspension cells.3. To each well with RNAi duplex - Lipofectamine™ RNAiMAX complexes, add500 µl of the diluted cells. This gives a final volume of 600 µl and a final RNA concentration of 10 nM. Mix gently by rocking the plate back and forth.4. Incubate the cells 24-72 hours at 37°C in a CO2 incubator until you are readyto assay for gene knockdown.Assessing Transfection EfficiencyTo qualitatively assess transfection efficiency, we recommend using a KIF11 Stealth™ Select RNAi (available through /rnaiexpress; for human cells, oligo HSS105842 is a good choice). Adherent cells in whichKIF11/Eg5 is knocked down exhibit a “rounded-up” phenotype after 24 hours due to a mitotic arrest (Weil, D. et al., Biotechniques (2002), 33: 1244-1248); slow growing cells may take up to 72 hours to display the rounded phenotype. Alternatively, growth inhibition can be assayed after 48-72 hours.Note: The BLOCK-iT™ Fluorescent Oligo (Cat. No. 2013) is optimized for use with Lipofectamine™ 2000, and is not recommended for Lipofectamine™ RNAiMAX.Page 3 Forward TransfectionUse this procedure to forward transfect Stealth™ RNAi or siRNA into mammalian cells in a 24-well format (for other formats, see Scaling Up or Down Transfections, page 4). In forward transfections, cells are plated in the wells, and the transfection mix is generally prepared and added the next day. Optimize transfections as described in Optimizing Transfections (page 3), especially if transfecting a mammalian cell line for the first time. All amounts and volumes are given on a per well basis.Note: For some cell lines (e.g. MCF-7 or HepG2), we recommend reverse transfections.1. One day before transfection, plate cells in 500 µl of growth medium withoutantibiotics such that they will be 30-50% confluent at the time of transfection.2. For each well to be transfected, prepare RNAi duplex-Lipofectamine™RNAiMAX complexes as follows:a. Dilute 6 pmol RNAi duplex in 50 µl Opti-MEM®I Reduced Serum Mediumwithout serum. Mix gently.b. Mix Lipofectamine™ RNAiMAX gently before use, then dilute 1 µl in 50 µlOpti-MEM® I Reduced Serum Medium. Mix gently.c. Combine the diluted RNAi duplex with the diluted Lipofectamine™RNAiMAX. Mix gently and incubate for 10-20 minutes at roomtemperature.3. Add the RNAi duplex-Lipofectamine™ RNAiMAX complexes to each wellcontaining cells. This gives a final volume of 600 µl and a final RNAconcentration of 10 nM. Mix gently by rocking the plate back and forth.4. Incubate the cells 24-48 hours at 37°C in a CO2 incubator until you areready to assay for gene knockdown. Medium may be changed after 4-6hours.Optimizing TransfectionsTo obtain the highest transfection efficiency and low non-specific effects, optimize transfection conditions by varying RNAi duplex and Lipofectamine™RNAiMAX concentrations. Test 0.6-30 pmol RNAi duplex (final concentration 1-50 nM) and 0.5-1.5 µl Lipofectamine™ RNAiMAX for 24-well format. For extended time course experiments (> 72 hours), consider a cell density that is 10-20% confluent 24 hours after plating.Note: The concentration of RNAi duplex required will vary depending on the efficacy of the duplex.Page 4 Scaling Up or Down TransfectionsTo transfect cells in different tissue culture formats, vary the amounts of Lipofectamine™ RNAiMAX, RNAi duplex, cells, and medium used in proportion to the relative surface area, as shown in the table.Culture vessel Rel.surf.area1Vol. ofplatingmediumDilutionmediumreversetransfectionDilutionmediumforwardtransfectionRNAi(pmol)RNAi(nM)Lipofect-amine™RNAiMAX296-well 0.2 100 µl 20 µl 2 x 10 µl 0.12-6 1-50 0.1-0.3 µl48-well 0.4 200 µl 40 µl 2 x 20 µl 0.24-12 1-50 0.2-0.6 µl24-well 1 500 µl 100 µl 2 x 50 µl 0.6-30 1-50 0.5-1.5 µl6-well 5 2.5 ml 500 µl 2 x 250 µl 3-150 1-50 2.5-7.5 µl60 mm 10 5 ml 1 ml 2 x 500 µl 6-300 1-50 5-15 µl100 mm 30 10 ml 2 ml 2 x 1 ml 12-600 1-50 15-35 µl1 Surface areas may vary depending on the manufacturer.2If the volume of Lipofectamine™ RNAiMAX is too small to dispense accurately, and you cannot pool dilutions, predilute Lipofectamine™ RNAiMAX 10-fold in Opti-MEM®I Reduced Serum Medium, and dispense a 10-fold higher amount (should be at least1.0 µl per well). Discard any unused diluted Lipofectamine™ RNAiMAX. Cotransfecting DNA and RNA using Lipofectamine™ RNAiMAX For cotransfections of plasmid DNA and Stealth™ RNAi or siRNA into mammalian cells, we recommend using Lipofectamine™ 2000 (Catalog no. 11668-027), which is superior for plasmid transfections. If you want to use Lipofectamine™ RNAiMAX for your cotransfections, perform a reverse transfection as described on page 2 with the following modifications:1a: Add 20 ng (for 24-well format) of plasmid DNA to the diluted RNAi duplex. 2: Add cells such that they will be 80-100% confluent 24 hours after plating.Purchaser NotificationThis product is covered by one or more Limited Use Label Licenses (see the Invitrogen catalog or our web-site, ). By the use of this product you accept the terms and conditions of all applicable Limited Use Label Licenses.Limited Use Label License No. 5Limited Use Label License No. 27©2006 Invitrogen Corporation. All rights reserved.。

北京春达科技有限公司专营进口体外诊断试剂工业原料，透析产品，纯化填料，标准品

北京春达科技有限公司专营进⼝体外诊断试剂⼯业原料，透析产品，纯化填料，标准品SCLPP209碱性磷酸酶3.1.3.1Alkaline phosphatase from Calf intestine-Activity: >30000 U/mlGlycerol solution-Mw: 100,000-Store at -20 °CSCMAD211苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Microorganism-Activity: >40 U/mgYellowish amorphous powder-Mw: 140,000-Store at -20 °CSCMDH18C苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Pig heart-Activity: >1250 U/mgprot.White amorphous powder-Mw:140,000-Store at -20 °CSCMDL100苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Microorganism-Activity: >60 U/mgWhite amorphous powder-Mw: 80,000-Store at -20 °CSCMUT11C变旋酶5.1.3.3Mutarotase from Porcine kidney-Activity: >1500 U/mgWhite amorphous powder-Mw: 40,000-Store at -20 °CSCMUT12C变旋酶5.1.3.3Mutarotase from Porcine kidney-Activity: >1000 U/mlAmmonium sulfate suspension-Mw: 40,000-Store at 2-8 °CSCNAL301唾液酸醛缩酶4.1.3.3N-Acetylneuraminic acid aldolase from MicroorganismActivity: >15 U/mg-Yellowish amorphous powderMw: 98,000-Store at -20 °CSCPCO301原⼉茶酸3,4双加氧酶1.13.11.3Protocatechuate 3,4-dioxygenase from Pseudomonas sp.Activity: >3 U/mg-Light brown amorphous powderMw: 700,000-Store at -20 °CSCPEO131过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade IActivity: >250 U/mg-Reddish-brown amorphous powderMw: 40,000-Store at -20 °CSCPEO301过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade I-Activity: >250 U/mgReddish-brown amorphous powder-Mw: 40,000-Store at -20°CSCPEO302过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade III-Activity: >110 U/mgReddish-brown amorphous powder-Mw: 40,000-Store at -20°CSCPHO12C磷脂酶D Phospholipase D from Streptomyces chromofuscus3.1.4.4Activity: >40 U/mg-Brown amorphous powderMw: 57,000-Store at -20 °CSCPNP301嘌呤核苷磷酸化酶2.4.2.1Purine-nucleoside phosphorylase from MicroorganismActivity: >15 U/mg-White amorphous powderMw: 120,000-Store at -20 °CSCPPC301磷酸烯醇式丙酮酸羧化酶4.1.1.31Phosphoenolpyruvate carboxylase from Corn leavesActivity: >5 U/mg-White amorphous powderMw: 390,000-Store at -20 °CSCPSP101脯氨酸特定的肽链内切酶3.4.21.26Proline specific endopeptidase from Flavobacterium sp.Activity: >5 U/mg-White amorphous powder-Mw: 78,000-Store at -20 °CSCPYK302L丙酮酸激酶2.7.1.40Pyruvate kinase from Rabbit muscle-Activity:＞2000 U/mlwhite ammonium sulphate suspension-Mw:237000-Store at 2-8℃SCPYO311丙酮酸氧化酶1.2.3.3Pyruvate oxidase from Microorganism-Activity: >1.5 U/mgYellowish amorphous powder-Mw: 260,000-Store at -20 °CSCSAO341肌氨酸氧化酶1.5.3.1Sarcosine oxidase from Microorganism-Activity: >8 U/mgYellowish amorphous powder-Mw: 65,000-Store at -20 °CSCSAO351肌氨酸氧化酶1.5.3.1Sarcosine oxidase from Microorganism-Activity: >8 U/mgYellowish amorphous powder-Mw: 43,000-Store at -20 °CSCSOD302超氧化物歧化酶1.15.1.1Superoxide dismutase from Bovine erythrocyte-Activity: >3000U/mgBluish-green amorphous powder-Mw: 32,000-Store at -20 °CSCUAO201尿酸酶1.7.3.3Uricase from Candida sp.-Activity: >4 U/mg-White amorphous powder-Mw: 120,000-Store at -20 °CSCUAO211尿酸酶1.7.3.3Uricase from Bacillus sp.-Activity:>1.5 U/mg-White amorphous powder-Mw: 150,000-Store at -20 °CSCURH10S脲酶3.5.1.5Urease from Jack bean-Activity: >220 U/mg-White amorphous powder-Mw: 480,000-Store at -20 °CSCURH16C脲素酶GUrease G from Jack bean-Activity: >150 U/mgWhite amorphous powder-Mw: 480,000-Store at -20 °C3.5.1.5SCURH201脲素酶Urease from Jack bean-Activity: >100 U/mgWhite amorphous powder-Mw: 480,000-Store at -20 °C3.5.1.5SCXTO212黄嘌呤氧化酶Xanthine oxidase from Microorganism-Activity: >10 U/mgReddish-brown amorphous powder-Mw: 160,000-Store at -20°C1.1.3.222.诊断与研究⽤的辅酶CODES PRODUCTS CAS #SCADP01C 腺苷5'-⼆磷酸单钾盐⼆⽔合物ADP-K.2H2O-Adenosine 5’-diphosphate monopotasium saltdihydrate-C10H14N5O10P2K.2H2O-Mw:501.30-Colorless crystals-Purity:>95 %72696-48-1SCADP22C 腺苷5’-⼆磷酸⼆钠盐ADP-Na2-Adenosine 5’-diphosphate disodium salt-C10H13N5O10P2Na2-Mw:471.20-White powder-Purity:>98 %16178-48-6SCAMP02C 腺苷-5’-磷酸AMP-Adenosine 5’-monophosphoric acid-C10H14N5O7P.H2O-Mw:365.20-White powder-Purity:>98 %18422-05-4SCAMP05C 腺苷5’-磷酸AMP-Na2-Adenosine 5’-monophosphate disodium salt -C10H12N5O7PNa2-Mw:391.18-White powder-Purity:>95%18422-05-4SCATP03C 腺苷5’-三磷酸⼆钠盐3⽔合物ATP-Na2.3H2O-Adenosine 5’-triphosphate disodium salttrihydrate -C10H14N5Na2O13P3.3H2O -Mw:605.19-White powder-Purity:>96 %987-65-5SCBNA207C β-烟酰胺-腺嘌呤⼆核苷酸NAD-β-Nicotinamide-adenine dinucleotide-C21H27N7O14P2-Mw:663.4-White powder-Purity:>98 %53-84-9SCBND210C β-烟酰胺腺嘌呤⼆核苷磷酸，还原型四钠盐NADPH-Na4-β-Nicotinamide-adenine dinucleotide phosphate, reducedtetrasodium salt-C21H26N7O17P3.Na4-Mw:833.40-White powder-Purity:>93 %2646-71-1SCBNH208C β-烟酰胺腺嘌呤⼆核苷酸，还原⼆钠盐NADH-Na2-β-Nicotinamide-adenine dinucleotide, reduceddisodium salt -C21H27N7P2O14Na2-Mw:709.40-White to yellowish powder-Purity:>93 %606-68-8β-烟酰胺腺嘌呤⼆核苷酸磷酸⼆钠盐24292-60-2SCBNP209C β-烟酰胺腺嘌呤⼆核苷酸磷酸⼆钠盐NADP-Na2-β-Nicotinamide-adenine dinucleotide phosphatedisodium salt-C21H26N7O17P3Na2-Mw:787.40-Yellowishpowder-Purity:>97 %24292-60-2SCCOA11C 辅酶A三锂盐Coenzyme A trilithium salt-C21H33Li3N16O7P3S-Mw:785.40-White powder-Purity:>85 %18439-24-2SCDAD631C ⼆(腺苷-5’-)五磷酸三锂盐Ap5A-Li3-P1,P5 –Di(adenosine -5’-)pentaphosphate trilithiumsalt-C20H26N10O22P5Li3-Mw:934.20-Yellowish powder-Purity:>95 %75522-97-3SCFAD11C 黄素腺嘌呤⼆核苷酸⼆钠盐FAD- Na2-Flavine-adenine dinucleotide disodium salt-C27H31N9O15P2Na2-Mw:829.60-Orange powder-Purity:>93 %146-14-5SCNAL24C N-⼄酰-L-半胱氨酸N-Acetyl-L-cysteine-C5H9NO3S-Mw:163.20-White powder-Purity:>98 %616-91-1SASNAD 硫代辅酶IThio-NAD-C21H27N7O13SP2-Purity:≥ 90%4090-29-3SASNADP 硫代辅酶IIThio-NADP-C21H27N7O16P3S•Na- Purity:≥ 90%19254-05-8SAAldNAD 3-吡啶⼄醛腺嘌呤⼆核苷酸3-Pyridinealdehyde adenine dinucleotide C21H27N6O14P21986-7-7SAAC1023-⼄酰基吡啶腺嘌呤⼆核苷酸磷酸钠(Ac-NADP) APADP-C22H28N6O17P3•Na -Purity:≥ 80%102029-67-4SANAAD 烟酸腺嘌呤⼆核苷酸Nicotinic Acid Adenine Dinucleotide- C21H26N6O15P2104809-30-5SADeNAD 脱氨基NADDeamino Nicotinamide Adenine Dinucleotide-C21H26N6O15P2104809-38-3SAGGNAFB γ-L-⾕氨酰基-4-硝基苯胺Gamma-L-glutamyl-4-nitroanilide,-C11H13N3O5-Purity:≥ 96%7300-59-6SACGGN L-γ-⾕氨酸-(3-甲酸-4硝基苯胺)铵盐L-Glutamic Acid Gamma- (3-Carboxy-4-Nitroanilide),Ammonium Salt-C12H12N3O7P•NH4-Purity:≥ 96%63699-78-5SAPEPCHA 磷酸烯醇丙酮酸单环⼰胺盐PEP-C3H4O6P•C6H13N-Purity :＞95%10526-80-4SAPEPK 磷酸烯醇式丙酮酸单钾盐PEP-C3H4O6P•K-Purity :＞95%4265-07-03.诊断与研究⽤的底物CODES PRODUCTS CAS #SCAKE05C α–酮戊⼆酸⼆钠盐⼆⽔合物α–Ketoglutaric acid, disodium salt dihydrate-C5H4O5Na2.2H2O-Mw:226.10 -White powder-Purity:>98%305-72-6α–酮戊⼆游离酸328-50-7SCAKE115C α–酮戊⼆游离酸α–Ketoglutaric free acid-C5H4O5-Mw:146.10 -White powder-Purity:>99%328-50-7SCBTC06S-丁酰硫胆碱碘S-Butyrylthiocholine Iodide-C9H20NOSI-Mw:317.23 -White powder-Purity:>97%1866-16-6SCCNP005Gal-G2-α-CNP-C28H51O18Cl-Mw:659.98 -White powder-Purity:>90 %157381-11-8SCCRP59C 磷酸肌酸⼆钠盐四⽔合物Phosphocreatine disodium salt tetrahydrate-C4H8N3O5PNa2.4H2O-Mw:327.15 -White powder-Purity:>97 %19333-65-4SCGGC106C ⽢氨酰⽢氨酸Glycylglycine-C4H8N2O3-Mw:132.12-White powder-Purity:>98 %556-50-3SCGLT100L-⾕氨酸L-Glutamic acid-C5H9N2O4- Mw:147.13-White powder-purity:＞99%617-65-2SCGPS15C 葡萄糖-6-磷酸⼆钠盐Glucose-6-phosphate disodium salt-C6H11O9PNa2-Mw:304.20-White powder-Purity:>95 %3671-99-6SCLAC171C DL-乳酸锂盐DL-Lactic acid Lithium salt-C3H5O3Li-Mw:96.01-White powder-Purity:>95%16891-53-5SCLAL29C L-丙氨酸游离酸L-Alanine free acid-C3H7NO2-Mw:89.09-White powder-Purity:>99%56-41-7SCLAP41C L-天门冬氨酸L-Aspartic acid-C4H7NO4-Mw:133.10-White powder-Purity:>99 %56-84-8SCLAP42C L-天门冬氨酸,钠盐⼀⽔合物L-Aspartic acid, sodium salt monohydrate-C4H6NO4Na.H2O-Mw:173.10-White powder-Purity:>98 %323194-76-9SCLAP43C L-天门冬氨酸,镁⼆⽔合物L-Aspartic acid, magnesium salt dihydrate-C8H12N2O8Mg.2H2O-MW:324.50-White powder-Purity:>98 %2068-80-6SCLGC244C L-γ-⾕氨酰-3-羧基-4-硝基苯胺Glupa C-L-γ-Glutamyl-3-carboxy-4-nitranilide-C12H12N3O7NH4-Mw:328.30-Yellow powder-Purity:>99 %63699-78-5SCNAY138C 萘磷酸单钠盐Naphtyl phosphate, monosodium salt-C10H8NaO4P.H2O-Mw:264.15-White powder-Purity:>98%81012-89-7SCPG701C 亚⼄基降-4-硝基苯基-β-D-麦芽庚糖苷pNP-G7-Ethylidene-4-nitrophenyl-D-maltoheptaoside-C50H77NO38-Mw:1300.10-Yellowish powder-Purity:>90%96597-16-9对硝基苯基磷酸酯，⼆钠盐六⽔合物4264-83-9SCPNP264C 对硝基苯基磷酸酯，⼆钠盐六⽔合物PNPP-p-Nitrophenylphosphate, disodium salt hexahydrate-C6H4NO6PNa2.6H2O-Mw :371.10-White to yellow powder-Purity:>98%4264-83-9SCPNS265C p-硝基苯基磷酸酯，⼆tris盐PNPP diTris-p-Nitrophenylphosphate, ditris salt-C14H28N3O12P-Mw:461.40-White powder68189-42-4SCPYN100丙酮酸钠Sodium pyruvate-C3H3NaO3-Mw:110-White powder-Purity:>99%113-24-64.缓冲液Buffers for diagnostic & researchPRODUCTS CAS # N-(2-⼄酰胺基)-2-氨基⼄磺酸ACES-N-(2-Acetamido)-2-aminoethanesulfonic acid7365-82-4N-(2-⼄酰胺基)亚氨基⼆⼄酸ADA-(N-(2-Acetamido)iminodiacetic acid)26239-55-4 2-氨基-2-甲基-1-丙醇AMT -2-amino-2-methyl-1-propanol124-68-5 N,N-双(2-羟⼄基)-2-氨基⼄磺酸BES-N,N-Bis-(2-Hydroxyethyl)-2-Aminoethanesulfonic acid10191-18-1 N,N-双-(2-羟基⼄基)⽢氨酸Bicine-N,N-Bis-(2-Hydroxyethyl)glycine150-25-4 N-环⼰基-3-氨基丙磺酸CAPS-N-Cyclohexyl-3-aminopropanesulfonicacid1135-40-6N-环⼰基-2-羟基-3-氨基丙磺酸CAPSO -N-Cyclohexyl-2-hydroxy-3-aminopropanesulfonic acid73463-39-5。

罗氏蛋白酶抑制剂说明

Pancreasextract
0.02
7.8 7.8
Thermolysin 0.0005 (Metalloprotease) Chymotrypsin Trypsin Papain 0.002 0.02 0.02 0.002 0.33
2.
How 7.8 7.8 7.8
For the complete inhibition of serine and cysteine proteases during extractions from animal and plant tissues or cells, yeast and bacteria
Cat. No. 04 693 159 001
0113.04728688001➂
Table 1: Inhibition of different proteases by cOmplete Protease Inhibitor Tablets. One cOmplete, EDTA-free tablet was added per 10 ml incubation solution. Proteolytic activity was determined with the Roche Applied Science Universal Protease Substrate (casein, resorufin-labeled*). When extractions or single-step isolations are necessary in the acid pH range, simply include pepstatin* along with cOmplete, EDTA-free tablets to ensure aspartic (acid) protease inhibition. All experiments were performed at room temperature.

无内毒素质粒小量提取试剂盒使用说明

9、向吸附柱中加入 700ul 漂洗液 (使用前请先检查是否已加入无水乙醇 )， 12000rpm 离心 1min，弃废液，将吸附柱放入收集管中。
10、向吸附柱中加入 500ul 漂洗液， 12000rpm 离心 1min，弃废液，将吸附柱放入收集管中。
3、向离心管中加入 200ul 溶液 P2，温和地上下翻转 6-8 次使菌体充分裂解。注意：混匀一定要温和，以免污染细菌基因组 DNA，此时菌液应变得清亮粘稠，作用时间不要超过 5 min，以免质粒受到破坏。
2. 洗脱缓冲液体积不应少于 50ul，体积过小影响回收效率；洗脱液的

pH 值对洗脱效率也有影晌，若需要用水做洗脱液应保证其 pH 值在 8.0 左右 (可用 NaOH 将水的 pH 值调至此范围 )， pH 值低于 7. 0 会降低洗脱效率。
由于质粒dna本身的性质清除过程可导致部分质粒dna丢失但内毒素却能得到最大限度清所有溶液应用无内毒素的高纯水配制所有器械材料均应不含内毒素玻璃器皿可高温烘烤非挥发性水溶液可高压处理

无内毒素质粒小量提取试剂盒使用说明货号： D1140 规格： 50T/100T 保存：常温干燥保存，复检期为一年。试剂盒内容：

有机化合物。内毒素清除剂可最大限度地除去内毒素。从 1-5ml 大肠杆菌 LB 培养液中，可快速提取 5-15μ g 高纯度质粒 DNA，提取率达 85-90%。使用本试剂盒提取的质粒 DNA 纯度高，可直接用于细胞转染等要求较高的实验，以及其他各种常规操作，包括酶切、 PCR、测序、连接和转化等试验。

Santa Cruz Biotechnology, Inc. 产品说明书

1. PRODUCT AND COMPANY IDENTIFICATIONProduct Name: 1,3-Dipalmitoyl-2-oleoylglycerolProduct Number:sc-213511Supplier:Santa Cruz Biotechnology, Inc.2145 Delaware AvenueSanta Cruz, CA 95060800.457.3801 or 831.457.3800Emergency:ChemWatchWithin the US & Canada: 877-715-9305Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 2. HAZARDS IDENTIFICATIONEmergency OverviewOSHA HazardsNo known OSHA hazardsGHS ClassiﬁcationChronic aquatic toxicity (Category 4)GHS Label elements, including precautionary statementsHazard statement(s)H413May cause long lasting harmful effects to aquatic life.Precautionary statement(s)noneHMIS ClassiﬁcationHealth hazard: 0Flammability: 0Physical hazards: 0NFPA RatingHealth hazard: 0Fire: 0Reactivity Hazard: 0Potential Health EffectsInhalation May be harmful if inhaled. May cause respiratory tract irritation.Skin May be harmful if absorbed through skin. May cause skin irritation.Eyes May cause eye irritation.Ingestion May be harmful if swallowed.3. COMPOSITION/INFORMATION ON INGREDIENTSSynonyms: 1,3-Dihexadecanoyl-2-(cis-9-octadecenoyl)glycerolFormula: C53H100O6Molecular Weight: 833.36CAS-No. EC-No. Index-No. Concentration 1,3-Dipalmitoyl-2-oleoylglycerol2190-25-2---4. FIRST AID MEASURESGeneral adviceConsult a physician. Show this safety data sheet to the doctor in attendance.If inhaledIf breathed in, move person into fresh air. If not breathing, give artiﬁcial respiration. Consult a physician.In case of skin contactWash off with soap and plenty of water. Consult a physician.In case of eye contactFlush eyes with water as a precaution.If swallowedNever give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.5. FIREFIGHTING MEASURESConditions of ﬂammabilityNot ﬂammable or combustible.Suitable extinguishing mediaUse water spray, alcohol-resistant foam, dry chemical or carbon dioxide.Special protective equipment for ﬁreﬁghtersWear self contained breathing apparatus for ﬁre ﬁghting if necessary.Hazardous combustion productsHazardous decomposition products formed under ﬁre conditions: carbon oxides6. ACCIDENTAL RELEASE MEASURESPersonal precautionsAvoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.Environmental precautionsPrevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided.Methods and materials for containment and cleaning upPick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.7. HANDLING AND STORAGEPrecautions for safe handlingProvide appropriate exhaust ventilation at places where dust is formed.Conditions for safe storageKeep container tightly closed in a dry and well-ventilated place. Store at -20 °C.8. EXPOSURE CONTROLS/PERSONAL PROTECTIONContains no substances with occupational exposure limit values.Personal protective equipmentRespiratory protectionRespiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).Hand protectionHandle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.Eye protectionUse equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).Skin and body protectionChoose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the speciﬁc work-place., The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the speciﬁc workplace.Hygiene measuresHandle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.9. PHYSICAL AND CHEMICAL PROPERTIESForm solid pH no data available Melting point/freezing point37.4 - 38.0 °C Boiling point no data available Flash point no data available Ignition temperature no data available Auto-ignition temperature no data available Lower explosion limit no data available Upper explosion limit no data available Vapor pressure no data available Density no data available Water solubility no data available Relative vapor density no data available Odor no data available Odor Threshold no data available Evaporation rate no data available Partition coefﬁcient (25 °C)log Pow: 22.22n-octanol/water10. STABILITY AND REACTIVITYChemical stabilityStable under recommended storage conditions.Possibility of hazardous reactionsno data availableConditions to avoidno data availableMaterials to avoidStrong oxidizing agentsHazardous decomposition productsHazardous decomposition products formed under ﬁre conditions: carbon oxidesOther decomposition productsno data available11. TOXICOLOGICAL INFORMATIONAcute toxicityOral LD50 no data availableInhalation LC50 no data availableDermal LD50 no data availableOther information on acute toxicity no data availableSkin corrosion/irritationno data availableSerious eye damage/eye irritationno data availableRespiratory or skin sensitizationno data availableGerm cell mutagenicityno data availableCarcinogenicityIARC: No component of this product present at levels greater than or equal to 0.1% is identiﬁed as probable, possible or conﬁrmed human carcinogen by IARC.ACGIH: No component of this product present at levels greater than or equal to 0.1% is identiﬁed as a carcinogen or potential carcinogen by ACGIH.NTP: No component of this product present at levels greater than or equal to 0.1% is identiﬁed as a known or anticipated carcinogen by NTP.OSHA: No component of this product present at levels greater than or equal to 0.1% is identiﬁed as a carcinogen or potential carcinogen by OSHA.Reproductive toxicityno data availableTeratogenicityno data availableSpeciﬁc target organ toxicity - single exposure (Globally Harmonized System)no data availableSpeciﬁc target organ toxicity - repeated exposure (Globally Harmonized System)no data availableAspiration hazardno data availablePotential health effectsInhalation May be harmful if inhaled. May cause respiratory tract irritation.Ingestion May be harmful if swallowed.Skin May be harmful if absorbed through skin. May cause skin irritation.Eyes May cause eye irritation.Synergistic effectsno data availableAdditional InformationRTECS: Not available12. ECOLOGICAL INFORMATIONToxicity Persistence and degradabilityno data available no data availableBioaccumulative potential Mobility in soilno data available no data availablePBT and vPvB assessment Other adverse effectsno data available An environmental hazard cannot be excluded in the eventof unprofessional handling or disposal.13. DISPOSAL CONSIDERATIONSProductOffer surplus and non-recyclable solutions to a licensed disposal company.Contaminated packagingDispose of as unused product.14. TRANSPORT INFORMATIONDOT (US) IMDG IATANot dangerous goods Not dangerous goods Not dangerous goods15. REGULATORY INFORMATIONOSHA HazardsNo known OSHA hazardsSARA 302 ComponentsSARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. SARA 313 ComponentsSARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 HazardsNo SARA HazardsMassachusetts Right To Know ComponentsNo components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components1,3-Dipalmitoyl-2-oleoylglycerol CAS-No. 2190-25-2 New Jersey Right To Know Components1,3-Dipalmitoyl-2-oleoylglycerol CAS-No. 2190-25-2 California Prop. 65 ComponentsThis product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.16. OTHER INFORMATIONThe above information is believed to be correct but does not purport to be complete and should be used only as a guide. The burden of safe use of this material rests entirely with the user.09/27/2013。

蛋白荧光染料大比拼

蛋白荧光染料大比拼【字体：大中小】时间：2009年11月20日0 来源：生物通------------------------------------------------------------------------------------------------------------------------------------摘要：随着蛋白质组学的发展，定量蛋白质组和多重分析越来越流行，考马斯蓝染色及银染已经无法满足更高的要求。

此时，荧光染料的优势就凸显出来。

生物通这就带大家看看市场上主流的蛋白荧光染料，包括总蛋白染料、磷酸化蛋白和糖基化蛋白染料。

另外，本文还会介绍一些特殊用途的荧光染料。

几十年来，聚丙烯酰胺凝胶电泳（PAGE）及相关的blot已经成为蛋白分析的主流技术。

考马斯蓝染色和银染也就成了我们最熟悉的染色方法。

不过，随着蛋白质组学的发展，定量蛋白质组和多重分析越来越流行，这些染料已经无法满足更高的要求。

此时，荧光染料的优势就凸显出来。

生物通这就带大家看看市场上主流的蛋白荧光染料，包括总蛋白染料、磷酸化蛋白和糖基化蛋白染料。

另外，本文还会介绍一些特殊用途的荧光染料。

总蛋白染料与传统的考马斯蓝染色相比，荧光染色可将检测的灵敏度降至1 ng以下，与银染相当；而与银染相比，荧光蛋白染料的线性范围比银染宽很多，一般可达3个数量级以上，且对不同种蛋白的染色强度变化小，与蛋白质量成清晰的线性关系，而不依赖于多肽序列及糖基化程度。

目前的荧光染色法与后续的质谱分析和Edman测序等技术兼容，因此无论在1D还是2D电泳领域都日渐受到研究人员的青睐。

蛋白荧光染料需要一个紫外光透射仪（下紫外）才能观察，当然，有激光扫描仪时效果更佳。

名气最大的总蛋白荧光染料当属Invitrogen旗下Molecular Probes公司持有专利的SYPRO® 荧光蛋白染料系列。

这一最早上市的荧光蛋白染料系列包括了SYPRO® Ruby，SYPRO® Red，SYPRO® Tangerine几种不同颜色。

免疫组化实验--全套试剂耗材

免疫组化实验试剂耗材大全华越洋---------------------------- 0.1%胰蛋白酶消化液waryong 10ml 110多聚甲醛merk 25g 504%多聚甲醛waryong 500ml 22010X多聚赖氨酸waryong 10ml 260抗荧光衰减封片剂waryong 25ml 230防脱载玻片waryong 50片310mayer'苏木素染液（免疫组化）waryong 100ml 410封闭用正常绵羊/山羊/兔/人血清waryong 10ml 75弗氏不完全佐剂sigma 10ml 180弗氏完全佐剂sigma 10ml 200柠檬酸钠缓冲液0.01mol/L PH6.0 waryong 1L 10DAB amresco 1g 13520XDAB显色液 A，B液各1.5ml waryong 3ml 95NBT amresco 100mg 95BCIP amresco 100mg 310BCIP/NBT底物显色试剂盒waryong 25ml 210PBST(PH7.4)抗体稀释液waryong 1ml 25一抗稀释液waryong 100ml 390HRP标记抗体稀释液waryong 100ml 390AP标记抗体稀释液waryong 100ml 390荧光抗体稀释液waryong 50ml 110免疫组化名称规格价格Super Polymer-二步法IHC试剂盒3ml35818ml1598兔Streptavidin-HRP试剂盒3ml19818ml998鼠Streptavidin-HRP试剂盒3ml19818ml998兔∕鼠通用型Streptavidin-HRP试剂盒3ml25818ml1198山羊抗兔IgG,Biotin(IHC工作液)3ml6818ml298山羊抗鼠IgG,Biotin(IHC工作液)3ml6818ml298山羊抗兔∕鼠IgG,Biotin(IHC工作液)3ml9818ml498 Streptavidin-HRP(IHC工作液)3ml9818ml49860ml258 AEC底物显色试剂盒20ml98 BCIP∕NBT碱性磷酸酶显色试剂盒(40x)40ml198 BCIP/NBT碱性磷酸酶显色试剂40ml229改良型苏木素(IHC常用复染试剂)10ml68柠檬酸缓冲液(IHC抗原修复液,100x)100ml68EDTA缓冲液(IHC抗原修复液，50x)100ml68封闭用正常山羊血清工作液(免疫组化封闭液)10ml68内源性过氧化物酶封闭液10ml68内源性碱性磷酸酶封闭液10ml68Biotin标记抗体稀释液20ml中性树胶100g98水性封片剂10ml98 Super Polymer-二步法IHC试剂盒（带DAB显色液）3ml39818ml1698兔Streptavidin-HRP试剂盒（带DAB显色液）3ml25818ml1098鼠Streptavidin-HRP试剂盒（带DAB显色液）3ml25818ml1098兔∕鼠通用型Streptavidin-HRP试剂盒（带DAB显色液）3ml29818ml1298。

liproxstatin-1结构

liproxstatin-1结构Liproxstatin-1是一种新型的神经保护剂，具有潜在的治疗神经退行性疾病的能力。

其化学式为C22H19N3O2S4，分子量为477.64 g/mol。

Liproxstatin-1是一种硫代劳氨酸衍生物，具有自由基清除剂的特性。

它可通过抑制蛋白质泛素化酶USP14，从而促进神经元的保护和废旧蛋白的降解。

在药物研究领域，确定药物的结构是至关重要的一步。

对于Liproxstatin-1，其结构可以通过多种方法确定。

其中包括质谱分析、核磁共振谱分析、X射线晶体结构分析等。

质谱分析可以用来确定Liproxstatin-1的分子量、分子式和它的裂解模式。

在质谱分析中，Liproxstatin-1的分子量可以通过电离源（如电子轰击、化学电离、MALDI等）进行测定。

此外，质谱分析也可以用来鉴定Liproxstatin-1的结构异构体和可能的污染物。

核磁共振谱分析（NMR）是确定有机分子结构的另一种方法。

通过NMR技术，可以获得关于分子的结构、环境、排布和化学键的详细信息。

Liproxstatin-1的NMR谱谱可以提供分子中的每个原子的所在位置和相邻基团的化学环境。

X射线晶体结构分析是一种确定有机分子结构的强大工具。

该技术可以通过将Liproxstatin-1晶体暴露在X射线束下，获得分子晶体的散射图像，进而确定该药物的三维结构。

这种方法可以提供药物结构的高分辨率3D图像，从而有助于深入了解药物分子的性质。

除了确定药物结构外，人们还可以通过计算化学方法预测Liproxstatin-1的异构体，分子较小的分子可能只存在一个异构体，而较大分子可能存在若干个异构体。

计算化学方法可以提供有关药物分子的立体结构、物理和化学性质的信息。

在药物研究领域，在确定药物结构的同时，还需要评估药物分子的可行性。

Liproxstatin-1的药理学特性和临床前科研数据表明，它是一种具有相当治疗潜力的神经保护剂，可以为治疗神经退行性疾病开辟一条新途径。